New York, NY -- September 27, 2022 -- InvestorsHub NewsWire --
via Stock Market Press -- Stock Market Press is a leading financial
news company that delivers up to date stock news. In today’s
release, we discuss Endexx Corp (OTC
PINK: EDXC), Northwest Biotherapeutics Inc (OTCQB:
NWBO), Anavex Life Sciences Corp (NASDAQ:
AVXL) and Enzolytics Inc (OTC
PINK: ENZC).
The vape industry is growing rapidly. Safety, variety,
non-nicotine options and more are driving the market forward. Grand
View Research indicated the 2021 market size was $18 billion with a
projected compounded annual growth rate of 30% through 2030. Endexx
Corp (OTC
PINK: EDXC) just completed the acquisition of HYLA, a plant
based, non-nicotine vape manufacturer.
Endexx’s HYLA Division Secures Two Purchase Orders Exceeding
200,000 Units
CAVE CREEK, AZ, Sept. 27, 2022 (GLOBE NEWSWIRE) -- via
NewMediaWire – Endexx Corporation (OTC:EDXC),
a provider of innovative, plant-based, and sustainable health and
skincare products, today announces that its recently acquired
(controlling-interest) HYLA division, secured two major purchase
orders for its new innovative vape-delivery product that holds 4500
puffs per built in cartridge unit.
Combined, the orders represent a 150,000-unit order and a
52,000-unit order for over 200,000 units within the first month of
the acquisition of Hyla. The newly innovated “No-Nic” (zero-
nicotine) vape product produced by HYLA offers 4500 puffs per
disposable unit. This expanded puff capacity far exceeds the
capacity of its competitor’s products worldwide. Formulated with
Guarana and Levodopa, this product is forecasted to replace the
recently banned nicotine products sold internationally where vape
products are available.
Todd Davis, CEO of Endexx, stated “HYLA’s new product line fills
a major gap created by the banning of flavored nicotine vape
products. We believe plant-derived products are the alternative and
the solution that meets market demands today. The two purchase
orders came from prominent distributors in the West Coast region of
the US and a large western region in Asia. These orders expand both
our international and domestic distribution networks helping to
expedite our growth initiatives.”
About Hyla
Hyla develops and distributes zero-nicotine plant-powered,
vape-delivered products made with vegan formulations and functional
plant extract ingredients. Hyla harnesses the power of Guarana and
Levodopa to create plant-derived high-performance botanical
products. For more information: www.tryHyla.com
About Endexx Corporation
Endexx Corporation develops and distributes all natural,
plant-derived topical skincare products. Its products vary
from balms, creams, lotions, butters, masks, scrubs, and oils, all
with the shared purpose of healthy skin and grooming wellness.
The science behind these products involves a decade of
clinical research in the field and lab work to provide functional
formulation with ingredients for optimal absorption and support of
skin health. www.endexx.com
Safe Harbor Statement Under the Private Securities Litigation
Reform Act of 1995
We caution that any forward-looking statements (as such term is
defined in the U.S. Private Securities Litigation Reform Act of
1995) contained in this press release or made by us, our
management, or our spokespeople involve risks and uncertainties and
are subject to change based on various factors, many of which are
beyond our control. Accordingly, our future performance and
financial results may differ materially from those expressed or
implied in any such forward-looking statements. Forward-looking
statements include, without limitation, statements regarding our
future operating results, the implementation and impact of our
strategic plans, and our ability to meet environmental, social, and
governance goals. Words such as “estimate,” “commit,” “target,”
“goal,” “project,” “plan,” “believe,” “seek,” “strive,” “expect,”
“anticipate,” “intend,” “potential” and any similar expressions may
identify forward-looking statements. Risks associated with the
following factors, among others, could affect our financial
performance and cause actual results to differ materially from
those expressed or implied in any forward-looking statements:
Except as may be required by law, we assume no obligation and do
not intend to make publicly available any update or other revisions
to any of the forward-looking statements contained in this press
release to reflect circumstances existing after the date of this
press release or to reflect the occurrence of future events, even
if experience or future events make it clear that any expected
results expressed or implied by those forward-looking statements
will not be realized. More information on potential factors that
could affect our results is included “Risk Factors” in our Annual
Report on Form 10-K filed with the Securities and Exchange
Commission on March 31, 2022.
For further information, please contact:
Endexx Corporation
Endexx@endexx.com
480-595-6900
Investors:
Scott Arnold
CORE IR
scotta@coreir.com
Media:
Jules Abraham
CORE IR
julesa@coreir.com
917-885-7378
Northwest Biotherapeutics (OTCQB:
NWBO) ("NW Bio"), a biotechnology company developing DCVax®
personalized immune therapies for solid tumor cancers, today
announced that it has received approval from the UK Medicines and
Healthcare Products Regulatory Agency (MHRA) for the Company's
Pediatric Investigation Plan (PIP). The development,
regulatory review and regulatory approval of a PIP is a
pre-requisite for application for approval of a new medicine for
adult patients, such as DCVax®-L.
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:
AVXL), a clinical-stage biopharmaceutical company developing
differentiated therapeutics for the treatment of neurodegenerative
and neurodevelopmental disorders including Alzheimer’s disease,
Parkinson’s disease, Rett syndrome and other central nervous system
(CNS) disorders, today announced that United States Patent and
Trademark Office (USPTO) issued U.S. Patent No. 11,446,275 to
Anavex, with claims to treatment methods using its leading drug
candidate, ANAVEX®2-73 (blarcamesine) and its analogs, for
ameliorating biochemical and functional abnormalities associated
with methyl-CpG binding protein 2 defects (MeCP2 defects).
Such defects encompass a range of neurodevelopmental and
neurological disorders, including but not limited to, Rett
syndrome, Angelman syndrome, Williams syndrome, cerebral palsy,
autism spectrum disorder, and multiple sclerosis.
Enzolytics Inc (OTC
PINK: ENZC) looks to have found a bottom over the past few
days. One to watch for a rebound back to the $0.055-$0.06 range
with any catalysts. Chart: https://www.stockscores.com/chart.asp?TickerSymbol=ENZC&TimeRange=180&Interval=d&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=1100&ChartHeight=480&LogScale=None&Band=BB&avgType1=SMA&movAvg1=50&avgType2=SMA&movAvg2=200&Indicator1=RSI&Indicator2=MACD&Indicator3=FStoch&Indicator4=SStoch&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen
Join Stock Market Press' newsletter for the latest in IPO,
market commentary and company profiles.
Stock Market Press is a financial news company that delivers up to
date stock news, introduces private and public companies to a wide
audience of investors, consumers, journalists and the general
public via social media and a rapidly expanding network.
Contact:
Stock Market Press
110 Wall St.
New York, NY 10005
info@stockmarketpress.com
https://twitter.com/PressStock
Safe Harbor Statement:
Statements in this news release may be ''forward-looking
statements.'' Forward-looking statements include, but are not
limited to, statements that express our intentions, beliefs,
expectations, strategies, predictions or any other statements
relating to our future activities or other future events or
conditions. These statements are based on current expectations,
estimates and projections about our business based, in part, on
assumptions made by management. These statements are not guarantees
of future performance and involve risks, uncertainties and
assumptions that are difficult to predict. Therefore, actual
outcomes and results may, and are likely to, differ materially from
what is expressed or forecasted in forward-looking statements due
to numerous factors. Any forward-looking statements speak only as
of the date of this news release and Stock Market Press undertakes
no obligation to update any forward-looking statement to reflect
events or circumstances after the date of this news release.
See Stock Market Press disclaimer: http://stockmarketpress.com/disclaimer/
SOURCE: Stock Market Press
Northwest Biotherapeutics (QB) (USOTC:NWBO)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024
Northwest Biotherapeutics (QB) (USOTC:NWBO)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024
